Webinars and Sponsored Roundtables — Register Now

Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.

Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

Laboratory information systems, 2024



 

[one_third]

[/one_third]

[one_third]

[/one_third]

[one_third_last]

[/one_third_last]

[wpdatatable id=110]

[one_third]


[/one_third]

[two_third_last]

LIS experts on HL7, AI, home-test results, and more

November 2024—Lab data displays, IT demands that outrun resources, at-home test results, and HL7 are some of what came up on Sept. 20 when CAP TODAY publisher Bob McGonnagle spoke online with pathologists and industry executives about laboratory information systems.

“It’s fire and forget,” said Ulysses G. J. Balis, MD, of the University of Michigan, about the lack of feedback from the EHR that a clinician has seen and understood a complex result. “Loss to follow-up is a real possibility,” he said.

Their conversation follows.

I’ll start with an overview of topics covered in last year’s roundtable on laboratory information systems. One is a need to integrate data between the LIS and EHR. We are still living in a world where dollars and staff are short and demands are diverse. Some clinicians want something concise; others want something complex and don’t want anything left out, which makes it difficult to simplify reporting. Ulysses Balis, can you comment on these dilemmas that everyone who does laboratory informatics faces?

Ulysses G. J. Balis, MD, associate chief medical information officer; A. James French professor of pathology informatics; director, Division of Pathology Informatics; and director, computational pathology laboratory section, Department of Pathology, Michigan Medicine, University of Michigan: The cumulative demands on the system, the lab, and the enterprise generally exceed available resources. We’ve shifted from generating simple lab results to the need for increasingly complex panels, molecular workflows, and derivative data, combined with downstream uses of that data, such as AI, where you need a specific format. Michigan is an exception to the rule in that we have retained ample technical resources to build such compound panels and interfaces. You have a growing queue of asks to the lab and the informatics group supporting the lab for data products, not just for the raw results but also the derivative data products that one generates with such results. These requests can take a long time to be realized or can’t be realized at all.

I see the list of requests growing faster than they’re getting resolved. I don’t know how we’ll solve this other than perhaps having standards for implementation of interfaces. We have HL7, and we know HL7 is almost a standard, but each place implements it slightly differently. Australians and New Zealanders have locked it down; I wish we could do that. The need and opportunity here is having one true interface implementation standard so we don’t have to do a complex dance of unit, load, and integration testing for every new lab or lab panel result requested, recognizing that the overhead needed to do this task has already become unsustainable.

Continue reading …
[/two_third_last]